Fresenius Settles NMC Violations With FDA, Justice Department
This article was originally published in The Gray Sheet
Executive Summary
Fresenius Medical Care AG expects to receive the court's okay within three months on a settlement reached with the FDA in connection with a series of GMP violations committed by subsidiary National Medical Care prior to September 1996.
You may also be interested in...
Fresenius Enters Eight Year "Corporate Integrity" Agreement With OIG
Fresenius Medical Care North America has agreed to an eight-year "corporate integrity" plan with the government as part of a final settlement with the HHS Office of the Inspector General announced Jan. 19.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.